KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Travere Therapeutics (TVTX) over the last 15 years, with Q3 2025 value amounting to $459.1 million.

  • Travere Therapeutics' Total Non-Current Liabilities fell 1147.12% to $459.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.1 million, marking a year-over-year decrease of 1147.12%. This contributed to the annual value of $528.3 million for FY2024, which is 857.26% down from last year.
  • Travere Therapeutics' Total Non-Current Liabilities amounted to $459.1 million in Q3 2025, which was down 1147.12% from $514.7 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Total Non-Current Liabilities registered a high of $620.3 million during Q4 2022, and its lowest value of $358.2 million during Q1 2021.
  • In the last 5 years, Travere Therapeutics' Total Non-Current Liabilities had a median value of $528.3 million in 2024 and averaged $508.3 million.
  • As far as peak fluctuations go, Travere Therapeutics' Total Non-Current Liabilities soared by 5264.68% in 2022, and later crashed by 1147.12% in 2025.
  • Quarter analysis of 5 years shows Travere Therapeutics' Total Non-Current Liabilities stood at $407.4 million in 2021, then surged by 52.26% to $620.3 million in 2022, then fell by 6.86% to $577.8 million in 2023, then dropped by 8.57% to $528.3 million in 2024, then fell by 13.09% to $459.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $459.1 million for Q3 2025, versus $514.7 million for Q2 2025 and $508.7 million for Q1 2025.